Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In
SIM - Scholars in Medicine Logo
SIM - Scholars in Medicine Logo
Founding Sponsors
Register

Dermatology

Unmasking the Mechanisms Behind "Ozempic Face": How GLP-1RAs May Accelerate Skin Aging

Jun 24, 2025

newspaper-banner

AT A GLANCE

This review explores the emerging mechanisms by which GLP-1 receptor agonists (GLP-1RAs) may contribute to skin aging, commonly observed as "Ozempic face." Beyond rapid weight loss, GLP-1RAs appear to impair adipose-derived stem cells and fibroblasts, reduce protective cytokine and collagen production, and increase oxidative stress—highlighting a multifactorial process that warrants further investigation.

While “Ozempic face” has been widely attributed to facial fat loss following GLP-1 receptor agonist (GLP-1RA) therapy, emerging research reveals that these medications may drive skin aging through direct cellular mechanisms. This review synthesizes recent findings that implicate GLP-1RAs in disrupting key skin cell functions involved in structural maintenance and repair.

GLP-1 receptors are expressed on adipose-derived stem cells (ADSCs) and fibroblasts—two critical players in dermal health. GLP-1RA stimulation appears to reduce cytokine production, impair glucose uptake, and trigger oxidative stress, all of which compromise fibroblast viability and collagen synthesis. The therapy may also suppress estrogen production in dermal white adipose tissue, further diminishing fibroblast activation and skin integrity.

Additionally, interactions with advanced glycation end products (AGEs) and their receptors (RAGEs) suggest a broader metabolic impact on the aging process. These multifactorial effects underscore that facial aging in GLP-1RA-treated patients is not merely cosmetic but rooted in complex, biologically driven pathways that warrant further investigation.

Reference: Paschou IA, Sali E, Paschou SA, et al. GLP-1RA and the possible skin aging. Endocrine. Published online June 11, 2025. doi:10.1007/s12020-025-04293-w

DRUG AT A GLANCE

GLP-1 Receptor Agonists (GLP-1RAs)

GLP-1 receptor agonists are a class of incretin-based therapies used primarily for type 2 diabetes and obesity management. They improve glycemic control and promote weight loss by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying.